Resources

This week we begin a new Homerun Slides series covering Hypo and Hyperglycemia from our Editor-in-chief, Dave Joffe, BSPharm, CDE, FACA, which will include facts and figures on this burgeoning epidemic.

Insulution Introduces the Daily Dose(TM) The World’s Smallest Syringe: Daily Dose is the world’s smallest insulin syringe and is designed to satisfy the requirement to be small, neat and convenient. Daily Dose is easily carried, for example, in a wallet or the cash pocket of jeans, so patients will have …

Thirty-five percent of the time for 250,000 newly diagnosed diabetes patients, physicians did not follow the ADA/EASD consensus guidelines for recommended treatment.…

The high cost of diagnosing peripheral neuropathy could be greatly reduced if doctors ordered the right tests.…

The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted overwhelmingly (20 to 2) in favor of approving the obesity drug Qnexa (Vivus, Inc.), a combination of phentermine and controlled-release topiramate. Qnexa could be the first prescription drug for obesity to reach the market since 1999.…

An FDA advisory committee’s endorsement of the anti-obesity drug Qnexa could re-energize the pharmaceutical industry after several years of disappointment in trying to develop anti-obesity drugs.…

In a reversal of two decades of medical reports, a Mayo Clinic study finds the frequency of nerve damage called diabetic polyneuropathy is similar in prediabetic patients and healthy people….

A new study contradicts previous studies showing no benefit to self-monitoring for new type 2’s, at least in the first year.…

Brain insulin may act as a satiety signal during the postprandial period and is associated with decreased appetite and reduced intake of highly palatable food….

Short-term treatment with liraglutide improved visceral fat adiposity, appetite, food preference and the urge for fat intake in obese Japanese patients with type 2 diabetes.…